A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (Anti-DLL4) in patients with previously treated solid tumors

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6295-6303

  Smith, David C ^a,f   Eisenberg, Peter D ^b   Manikhas, Georgy ^c   Chugh, Rashmi ^a   Gubens, Matthew A ^d   Stagg, Robert J ^e   Kapoun, Ann M ^e   Xu, Lu ^e   Dupont, Jakob ^e   Sikic, Branimir ^d  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b Marin Specialty Care   (United States)

^c City Oncology Dispensary St Petersburg   (Russian Federation)

^d STANFORD UNIVERSITY   (United States)

^e OncoMed Pharmaceuticals Inc   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CREATININE; DEMCIZUMAB; NOTCH RECEPTOR; WNT PROTEIN; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; SIGNAL PEPTIDE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPIRATION PNEUMONIA; ATELECTASIS; BLADDER TUMOR; BLEEDING; BLOOD SAMPLING; BRAIN METASTASIS; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CAUSE OF DEATH; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLEAR CELL CARCINOMA; CLEAR CELL SARCOMA; COHORT ANALYSIS; COLITIS; COLORECTAL CANCER; COLORECTAL TUMOR; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS TUMOR; FATIGUE; FEMALE; FLANK PAIN; GRANULOSA CELL TUMOR; HAIR FOLLICLE; HEAD AND NECK TUMOR; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HISTIOCYTOMA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPONATREMIA; IMMUNOGENICITY; KIDNEY CARCINOMA; KIDNEY TUMOR; LEIOMYOSARCOMA; LUNG EMBOLISM; LUNG INFARCTION; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEURALGIA; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; OCULAR MELANOMA; OVARIAN GRANULOSA CELL CARCINOMA; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS TUMOR; PENIS TUMOR; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA; PLEOMORPHIC SARCOMA; PLEURAL PAIN; PROSTATE TUMOR; SALIVARY GLAND TUMOR; SARCOMA; SIDE EFFECT; SOLID TUMOR; STOMACH TUMOR; SYNOVIAL SARCOMA; TESTIS TUMOR; TREATMENT DURATION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STAGING; CANCER STEM CELL; CLINICAL TRIAL; DRUG EFFECTS; DRUG MONITORING; METABOLISM; MIDDLE AGED; NEOPLASMS; RETREATMENT; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; NEOPLASTIC STEM CELLS; RETREATMENT; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84919621242     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1373     Document Type: Conference Paper

References (19)

1. Kopan R, Ilagan MX. The canonicalNotch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
2. Wilson A, Radtke F. Multiple functions of Notch signaling in selfrenewing organs and cancer. FEBS Lett 2006;580:2860-8.
3. Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to notch targeting as cancer therapy. Clin Cancer Res 2012;18:1588-95
4. Rizzo P, Osipo C, Forman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008; 27:5124-31
5. Pannuti A, Foreman K, Rizzo P, Osips C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16: 3141-52.
6. Besseyrias V, Fiorini E, Strobl LJ, Zimber-Strobi U, Dumortier A, Koch U, et al. Hierarchy of notch-delta interactions promoting T cell lineage commitment and maturation. JEM 2007;204: 331-43.
7. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 2013;19:1972-80.
8. Kang M, Jiang B, Xu B, Lu W, Guo Q, Xie Q, et al. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett 2013;330: 11-21.
9. Martinez JC, Muller MM, Turley H, Steers G, Choteau L, Li JL, et al. Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues (Retracted Article. See vol 55, pg 463, 2009). Histopathology 2009;54: 598-606.
10. Mailhos C, Modlich U, Lewis J, Harris A, Bickness R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expessed at sites of physiological and tumor angiogenesis. Differentiation 2001;69: 135-44.
11. William C, Li J-L, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006;107:931-9.
12. Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 2007;13:7243-6.
13. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5.
14. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
15. Yen WC, Fischer MM, Hynes M, Wu J, Kim E, Beviglia L, et al. Anti- DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin Cancer Res 2012;18.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment inn solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000;92:205-16.
17. Efron B, Tibshirani R. Bootstrap confidence intervals, confidence intervals and other methods of statistical accuracy. Stat Sci 1986;1:54-75.
18. DiCiccio T, Efron B. Bootstrap confidence intervals. Stat Sci 1996;11: 189-229.
19. Jimeno A, LoRusso P, Strother RM, Diamond JR, Plato L, Younger A, et al. Phase I study of REGN421 (R)/SAR153192, a fully-human deltalike ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors. J Clin Oncol 2013;31.